{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T06:15:22Z","timestamp":1783577722946,"version":"3.55.0"},"reference-count":138,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Substance use disorders (SUDs) and treatment-resistant depression (TRD) remain a major global health challenge, marked by high relapse rates and limited long-term effectiveness of existing treatments. Ketamine, a glutamatergic modulator with rapid neuroplastic effects, has emerged as a novel intervention for TRD and is increasingly investigated as an adjunctive treatment for addiction, yet concerns about its abuse liability persist.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This review critically evaluates ketamine\u2019s therapeutic potential for SUDs while examining its neurobiological mechanisms, clinical efficacy, and risk of misuse within a unified risk\u2013benefit framework.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A structured narrative review conducted in accordance with the SANRA framework using the PubMed, Scopus, PsycINFO, and Web of Science databases, covering literature published until March 2026. Eligible studies included clinical trials, experimental studies, and mechanistic investigations relevant to ketamine use in addiction and depression. Evidence was synthesized thematically across the domains of efficacy, mechanisms, and safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Across alcohol and cocaine use disorders, ketamine combined with psychotherapy has demonstrated promising reductions in craving and increases in abstinent days in small-to moderate-sized Phase 2 trials. However, findings remain difficult to generalize due to considerable variability in dosing strategies, comparator conditions, and follow-up periods. Effects on relapse prevention have been more inconsistent and less reliably positive. Mechanistically, ketamine promotes synaptic plasticity via NMDA receptor antagonism and downstream glutamatergic signaling, potentially disrupting maladaptive reward-related memories and reversing maladaptive neurocircuitry involved in both depression and addiction. While acute adverse effects are generally transient under clinical supervision, ketamine carries a well-established risk of misuse, particularly in unsupervised or high-dose settings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Ketamine represents a promising but still experimental intervention for both refractory depression and selected SUDs. Its clinical use depends on careful patient selection, structured delivery, and integration with psychotherapy. Although ketamine may redefine treatment paradigms for TRD and addiction, larger-scale trials and long-term safety data are essential to define its role within psychiatric and addiction treatment frameworks.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fpsyt.2026.1866092","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T05:34:41Z","timestamp":1783575281000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Treating addiction with an addictive drug: the ketamine paradox revisited"],"prefix":"10.3389","volume":"17","author":[{"given":"Alqassem Y.","family":"Hakami","sequence":"first","affiliation":[{"name":"College of Medicine, King Saud Bin Abdulaziz University for Health Sciences","place":["Jeddah, Saudi Arabia"]},{"name":"King Abdullah International Medical Research Center","place":["Jeddah, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1002\/wps.21073","article-title":"Substance use disorders: a comprehensive update of classification, epidemiology, neurobiology, clinical aspects, treatment and prevention","volume":"22","author":"Volkow","year":"2023","journal-title":"World Psychiatry"},{"key":"B2","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-031-72219-6_14","article-title":"Neurobiology of addiction","volume-title":"Psychiatry and Neuroscience Update\u2013Vol V: Addiction: From Laboratory and Anthropology to Clinical Practice","author":"Bourin","year":"2024"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.2147\/sar.s145201","article-title":"Mindfulness meditation in the treatment of substance use disorders and preventing future relapse: neurocognitive mechanisms and clinical implications","volume":"9","author":"Priddy","year":"2018","journal-title":"Subst Abuse Rehabil"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.pbb.2024.173787","article-title":"Behavioral therapies targeting reward mechanisms in substance use disorders","volume":"240","author":"Wardle","year":"2024","journal-title":"Pharmacol Biochem Behav"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.33425\/2639-8451.1054","article-title":"Evidence-based addiction treatment comparison: a comprehensive analysis of substance use and process addictions","volume":"9","author":"Ungar-Sargon","year":"2025","journal-title":"Addict Res"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1172\/jci172883","article-title":"Stress and substance use disorders: risk, relapse, and treatment outcomes","volume":"134","author":"Sinha","year":"2024","journal-title":"J Clin Invest"},{"key":"B7","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1080\/10550887.2024.2440184","article-title":"Neurobiology, psychotherapeutic interventions, and emerging therapies in addiction: a systematic review","volume":"44","author":"Lomas","year":"2026","journal-title":"J Addictive Dis"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2025.106311","article-title":"Precision medicine in substance use disorders: integrating behavioral, environmental, and biological insights","volume":"176","author":"Guerrin","year":"2025","journal-title":"Neurosci Biobehav Rev"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1159\/000525268","article-title":"The treatment of substance use disorders: recent developments and new perspectives","volume":"81","author":"Rosenthal","year":"2022","journal-title":"Neuropsychobiology"},{"key":"B10","first-page":"3","article-title":"Predictors of relapse in alcohol use disorder: identifying individuals most vulnerable to relapse","volume":"1","author":"Stillman","year":"2020","journal-title":"Addict Subst Abuse"},{"key":"B11","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1124\/pharmrev.120.000083","article-title":"Drug addiction: hyperkatifeia\/negative reinforcement as a framework for medications development","volume":"73","author":"Koob","year":"2021","journal-title":"Pharmacol Rev"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2024.111070","article-title":"Advancements in addressing drug dependence: a review of promising therapeutic strategies and interventions","volume":"134","author":"Guida","year":"2024","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1093\/psyrad\/kkac021","article-title":"Neurobiological mechanisms and related clinical treatment of addiction: a review","volume":"2","author":"Fang","year":"2022","journal-title":"Psychoradiology"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.11406","article-title":"Diagnosis and pharmacotherapy of alcohol use disorder: a review","volume":"320","author":"Kranzler","year":"2018","journal-title":"Jama"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01670-3","article-title":"Novel agents for the pharmacological treatment of alcohol use disorder","volume":"82","author":"Burnette","year":"2022","journal-title":"Drugs"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.19761","article-title":"Pharmacotherapy for alcohol use disorder: a systematic review and meta-analysis","volume":"330","author":"McPheeters","year":"2023","journal-title":"Jama"},{"key":"B17","article-title":"Evidence-based pharmacotherapies for alcohol use disorder: clinical pearls","volume":"95","author":"Fairbanks","year":"2020","journal-title":"InMayo Clinic Proc"},{"key":"B18","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1111\/acps.13802","article-title":"Pharmacological treatments in alcohol use disorder and risk of alcohol\u2010related hospitalizations: a register study","volume":"152","author":"Bach","year":"2025","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.18103\/mra.v13i2.6328","article-title":"Pharmacotherapy for alcohol use disorder: a comprehensive review of current treatments and future directions","volume":"13","author":"Legan","year":"2025","journal-title":"Med Res Arch"},{"key":"B20","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2022.0395","article-title":"Treatment of tobacco smoking: a review","volume":"327","author":"Rigotti","year":"2022","journal-title":"Jama"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2073","article-title":"Current and emerging pharmacotherapies for cessation of tobacco smoking","volume":"38","author":"G\u00f3mez\u2010Coronado","year":"2018","journal-title":"Pharmacother: J Hum Pharmacol Drug Ther"},{"key":"B22","doi-asserted-by":"publisher","first-page":"95","DOI":"10.12775\/JEHS.2023.36.01.010","article-title":"An integrated approach to pharmacotherapy in smoking cessation: the role of varenicline, bupropion, cytisine, and nicotine replacement therapy","volume":"36","author":"Wi\u0119c\u0142aw","year":"2023","journal-title":"J Education Health Sport"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.1012433","article-title":"Pharmacological interventions on smoking cessation: a systematic review and network meta-analysis","volume":"13","author":"Shang","year":"2022","journal-title":"Front Pharmacol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-020-00711-x","article-title":"Pharmacological treatment of methamphetamine\/amphetamine dependence: a systematic review","volume":"34","author":"Siefried","year":"2020","journal-title":"CNS Drugs"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/add.14755","article-title":"Pharmacotherapy for methamphetamine\/amphetamine use disorder\u2014a systematic review and meta\u2010analysis","volume":"114","author":"Chan","year":"2019","journal-title":"Addiction"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.2147\/sar.s431273","article-title":"Pharmacological treatments for methamphetamine use disorder: current status and future targets","volume":"15","author":"Yates","year":"2024","journal-title":"Subst Abuse Rehabil"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2017.1313229","article-title":"Pharmacotherapeutic agents in the treatment of methamphetamine dependence","volume":"26","author":"Morley","year":"2017","journal-title":"Expert Opin Invest Drugs"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.conb.2024.102898","article-title":"Novel therapeutics in development for the treatment of stimulant-use disorder","volume":"87","author":"Young","year":"2024","journal-title":"Curr Opin Neurobiol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41572-021-00247-4","article-title":"Cannabis use and cannabis use disorder","volume":"7","author":"Connor","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.8049","article-title":"Comparison of treatments for cocaine use disorder among adults: a systematic review and meta-analysis","volume":"4","author":"Bentzley","year":"2021","journal-title":"JAMA Netw Open"},{"key":"B31","doi-asserted-by":"publisher","first-page":"206","DOI":"10.5152\/alphapsychiatry.2024.241522","article-title":"Ketamine in substance use disorder treatment: a narrative review","volume":"25","author":"Famu\u0142a","year":"2024","journal-title":"Alpha Psychiatry"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3390\/neurosci6030083","article-title":"Ketamine\u2019s therapeutic role in substance use disorders: a narrative review","volume":"6","author":"Thomas","year":"2025","journal-title":"Neurosci"},{"key":"B33","doi-asserted-by":"publisher","first-page":"111461","DOI":"10.1016\/j.pnpbp.2025.111461","article-title":"An overview of psilocybin, LSD, MDMA, and ketamine in revitalizing psychedelic-assisted therapy: insights, limitations and future directions","volume":"141","author":"Askariyan","year":"2025","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2023.1156319","article-title":"Mini-review: the neurobiology of treating substance use disorders with classical psychedelics","volume":"17","author":"Urban","year":"2023","journal-title":"Front Neurosci"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.cobeha.2016.10.009","article-title":"Tripping up addiction: the use of psychedelic drugs in the treatment of problematic drug and alcohol use","volume":"13","author":"Morgan","year":"2017","journal-title":"Curr Opin Behav Sci"},{"key":"B36","doi-asserted-by":"publisher","first-page":"2824","DOI":"10.3390\/molecules30132824","article-title":"Ketamine\u2014From an anesthetic to a psychiatric drug: mechanisms of action, clinical applications and potential risks","volume":"30","author":"Gibu\u0142a-Tar\u0142owska","year":"2025","journal-title":"Molecules"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/s0924-977x(17)30999-9","article-title":"NMDAR inhibition-independent antidepressant actions of ketamine metabolites","volume":"533","author":"Zanos","year":"2016","journal-title":"Nature"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-021-01093-2","article-title":"Pharmacological and behavioral divergence of ketamine enantiomers: implications for abuse liability","volume":"26","author":"Bonaventura","year":"2021","journal-title":"Mol Psychiatry"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2017.16","article-title":"Targeting glutamate signalling in depression: progress and prospects","volume":"16","author":"Murrough","year":"2017","journal-title":"Nat Rev Drug Discov"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1007\/s11916-025-01437-5","article-title":"Efficacy of ketamine infusion for treatment of opioid use disorder in patients with chronic pain: a narrative review","volume":"30","author":"Kaye","year":"2026","journal-title":"Curr Pain Headache Rep"},{"key":"B41","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1192\/j.eurpsy.2025.466","article-title":"Is there a risk of addiction to ketamine during the treatment of depression? a systematic review of available literature","volume":"39","author":"Ingrosso","year":"2025","journal-title":"J Psychopharmacol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1192\/bjo.2021.1061","article-title":"Ketamine for the treatment of mental health and substance use disorders: comprehensive systematic review","volume":"8","author":"Walsh","year":"2022","journal-title":"BJPsych Open"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychires.2022.04.035","article-title":"The abuse liability of ketamine: a scoping review of preclinical and clinical studies","volume":"151","author":"Le","year":"2022","journal-title":"J Psychiatr Res"},{"key":"B44","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s44192-024-00077-2","article-title":"Beyond therapeutic potential: a systematic investigation of ketamine misuse in patients with depressive disorders","volume":"4","author":"Juneja","year":"2024","journal-title":"Discover Ment Health"},{"key":"B45","doi-asserted-by":"crossref","DOI":"10.1007\/978-981-15-2902-3_1","article-title":"Ketamine abuse: past and present","volume-title":"Ketamine: From Abused Drug to Rapid-Acting Antidepressant","author":"Huang","year":"2020"},{"key":"B46","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s41073-019-0064-8","article-title":"SANRA\u2014a scale for the quality assessment of narrative review articles","volume":"4","author":"Baethge","year":"2019","journal-title":"Res Integrity Peer Rev"},{"key":"B47","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.neuropharm.2018.01.017","article-title":"Ketamine for the treatment of addiction: evidence and potential mechanisms","volume":"142","author":"Ezquerra-Romano","year":"2018","journal-title":"Neuropharmacology"},{"key":"B48","article-title":"Psychedelics in the treatment of substance use disorders and psychosis","volume":"62","author":"van den Brink","year":"2020","journal-title":"Tijdschrift Voor Psychiatr"},{"key":"B49","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/s2215-0366(17)30272-9","article-title":"Side-effects associated with ketamine use in depression: a systematic review","volume":"5","author":"Short","year":"2018","journal-title":"Lancet Psychiatry"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2025.01.054","article-title":"Hepatic adverse events associated with ketamine and esketamine: A population-based disproportionality analysis","volume":"374","author":"Kwan","year":"2025","journal-title":"J Affect Disord"},{"key":"B51","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1080\/14740338.2021.1949454","article-title":"Harm related to recreational ketamine use and its relevance for the clinical use of ketamine. A systematic review and comparison study","volume":"21","author":"Van Amsterdam","year":"2022","journal-title":"Expert Opin Drug Saf"},{"key":"B52","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41386-023-01629-w","article-title":"Ketamine and rapid antidepressant action: new treatments and novel synaptic signaling mechanisms","volume":"49","author":"Krystal","year":"2024","journal-title":"Neuropsychopharmacology"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3390\/psychoactives4030020","article-title":"Ketamine and esketamine in psychiatry: A comparative review emphasizing neuroplasticity and clinical applications","volume":"4","author":"Mikellides","year":"2025","journal-title":"Psychoactives"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.7554\/elife.86022","article-title":"Ketamine\u2019s rapid antidepressant effects are mediated by Ca2+-permeable AMPA receptors","volume":"12","author":"Zaytseva","year":"2023","journal-title":"Elife"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2024.09.008","article-title":"Ketamine and hydroxynorketamine as novel pharmacotherapies for the treatment of opioid use disorders","volume":"97","author":"Onisiforou","year":"2025","journal-title":"Biol Psychiatry"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2025.11.021","article-title":"Bifunctional modulation of NMDA and opioid receptors in ketamine reinforcement and misuse: implications for substance use disorder treatment","author":"Levinstein","year":"2025","journal-title":"Biol Psychiatry"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.josat.2025.209705","article-title":"Role of ketamine in the treatment of substance use disorders: A systematic review","volume":"175","author":"Janssen-Aguilar","year":"2025","journal-title":"J Subst Use Addict Treat"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1038\/nrn2590","article-title":"A single standard for memory: the case for reconsolidation","volume":"10","author":"Nader","year":"2009","journal-title":"Nat Rev Neurosci"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.tins.2009.05.002","article-title":"Reconsolidation: maintaining memory relevance","volume":"32","author":"Lee","year":"2009","journal-title":"Trends Neurosci"},{"key":"B60","doi-asserted-by":"publisher","first-page":"5187","DOI":"10.1016\/j.biopsych.2020.02.498","article-title":"Ketamine can reduce harmful drinking by pharmacologically rewriting drinking memories","volume":"10","author":"Das","year":"2019","journal-title":"Nat Commun"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1177\/0269881120970879","article-title":"Mystical-type experiences occasioned by ketamine mediate its impact on at-risk drinking: Results from a randomized, controlled trial","volume":"35","author":"Rothberg","year":"2021","journal-title":"J Psychopharmacol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/s2215-0366(16)00104-8","article-title":"Neurobiology of addiction: a neurocircuitry analysis","volume":"3","author":"Koob","year":"2016","journal-title":"Lancet Psychiatry"},{"key":"B63","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.drugalcdep.2015.05.031","article-title":"Prevalence of comorbid substance use, anxiety and mood disorders in epidemiological surveys, 1990\u20132014: A systematic review and meta-analysis","volume":"154","author":"Lai","year":"2015","journal-title":"Drug Alcohol Depend"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/b978-0-323-91497-0.00236-8","article-title":"Adjunctive ketamine with relapse prevention\u2013based psychological therapy in the treatment of alcohol use disorder","volume":"179","author":"Grabski","year":"2022","journal-title":"Am J Psychiatry"},{"key":"B65","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/s13063-017-1895-6","article-title":"A proof-of-concept investigation into ketamine as a pharmacological treatment for alcohol dependence: study protocol for a randomised controlled trial","volume":"18","author":"McAndrew","year":"2017","journal-title":"Trials"},{"key":"B66","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s13722-022-00345-y","article-title":"Single-dose intravenous ketamine or intramuscular naltrexone for high-utilization inpatients with alcohol use disorder: pilot trial feasibility and readmission rates","volume":"17","author":"Terasaki","year":"2022","journal-title":"Addict Sci Clin Pract"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2019.19070684","article-title":"A single ketamine infusion combined with motivational enhancement therapy for alcohol use disorder: a randomized midazolam-controlled pilot trial","volume":"177","author":"Dakwar","year":"2020","journal-title":"Am J Psychiatry"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.38498","article-title":"Ketamine treatment for alcohol use disorder: a systematic review","volume":"15","author":"Kelson","year":"2023","journal-title":"Cureus"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2022.109606","article-title":"Efficacy of ketamine intervention to decrease alcohol use, cravings, and withdrawal symptoms in adults with problematic alcohol use or alcohol use disorder: A systematic review and comprehensive analysis of mechanism of actions","volume":"239","author":"Garel","year":"2022","journal-title":"Drug Alcohol Depend"},{"key":"B70","doi-asserted-by":"publisher","first-page":"S471","DOI":"10.1192\/j.eurpsy.2025.976","article-title":"Ketamine treatment for alcohol use disorder: A review","volume":"68","author":"Peixoto","year":"2025","journal-title":"Eur Psychiatry"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2023.1141836","article-title":"The therapeutic use and efficacy of ketamine in alcohol use disorder and alcohol withdrawal syndrome: a scoping review","volume":"14","author":"Goldfine","year":"2023","journal-title":"Front Psychiatry"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.4103\/aip.aip_110_24","article-title":"Ketamine therapy in patients of alcohol use disorder: A prospective pilot study to evaluate abstinence rate with this add-on treatment modality","volume":"8","author":"Marvania","year":"2024","journal-title":"Ann Indian Psychiatry"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1080\/00952990.2025.2535559","article-title":"Safety and efficacy of ketamine for the treatment of patients with alcohol use disorder: a systematic review","volume":"51","author":"Rathore","year":"2025","journal-title":"Am J Drug Alcohol Abuse"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1177\/02698811241254834","article-title":"Esketamine combined with a mindfulness-based intervention for individuals with alcohol problems","volume":"38","author":"Gent","year":"2024","journal-title":"J Psychopharmacol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2019.18101123","article-title":"A single ketamine infusion combined with mindfulness-based behavioral modification to treat cocaine dependence: a randomized clinical trial","volume":"176","author":"Dakwar","year":"2019","journal-title":"Am J Psychiatry"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.51731\/cjht.2024.845","article-title":"Ketamine for adults with substance use disorders","volume":"4","author":"Tran","year":"2024","journal-title":"Can J Health Technol"},{"key":"B77","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1038\/mp.2016.39","article-title":"Cocaine self-administration disrupted by the N-methyl-D-aspartate receptor antagonist ketamine: a randomized, crossover trial","volume":"22","author":"Dakwar","year":"2017","journal-title":"Mol Psychiatry"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2013.08.009","article-title":"The effects of subanesthetic ketamine infusions on motivation to quit and cue-induced craving in cocaine-dependent research volunteers","volume":"76","author":"Dakwar","year":"2014","journal-title":"Biol Psychiatry"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2025.1552084","article-title":"Ketamine in treating opioid use disorder and opioid withdrawal: a scoping review","volume":"16","author":"Shen","year":"2025","journal-title":"Front Psychiatry"},{"key":"B80","article-title":"Effects of ketamine on precipitated opiate withdrawal","volume":"42","author":"Jovai\u0161a","year":"2006","journal-title":"Med (Kaunas)"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2019.06.020","article-title":"Medication treatment of opioid use disorder","volume":"87","author":"Bell","year":"2020","journal-title":"Biol Psychiatry"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1111\/add.70000","article-title":"Relative risks of adverse effects across different opioid agonist treatments\u2014A systematic review and meta\u2010analysis","volume":"120","author":"Meyer","year":"2025","journal-title":"Addiction"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2018.00277","article-title":"Efficacy of ketamine in the treatment of substance use disorders: a systematic review","volume":"9","author":"Jones","year":"2018","journal-title":"Front Psychiatry"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2025.116446","article-title":"The therapeutic effects of psychedelics for opioid use disorder: A systematic review of clinical studies","volume":"348","author":"Weleff","year":"2025","journal-title":"Psychiatry Res"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1093\/ijnp\/pyz039","article-title":"Efficacy and safety of fixed-dose esketamine nasal spray combined with a new oral antidepressant in treatment-resistant depression: results of a randomized, double-blind, active-controlled study (TRANSFORM-1)","volume":"22","author":"Fedgchin","year":"2019","journal-title":"Int J Neuropsychopharmacol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.0c01193","article-title":"Repurposing of drugs\u2013the ketamine story","volume":"63","author":"Das","year":"2020","journal-title":"J Med Chem"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2022.2066651","article-title":"Long-term safety of ketamine and esketamine in treatment of depression","volume":"21","author":"Nikayin","year":"2022","journal-title":"Expert Opin Drug Saf"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1007\/s44192-022-00012-3","article-title":"Ketamine treatment for depression: a review","volume":"2","author":"Yavi","year":"2022","journal-title":"Discover Ment Health"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2024.03.137","article-title":"Efficacy of intravenous racemic ketamine and intranasal esketamine with dose escalation for treatment-resistant depression: A systematic review and meta-analysis","volume":"356","author":"Seshadri","year":"2024","journal-title":"J Affect Disord"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2020.09.007","article-title":"A systematic review and meta-analysis of the efficacy of intravenous ketamine infusion for treatment resistant depression: January 2009\u2013January 2019","volume":"277","author":"Marcantoni","year":"2020","journal-title":"J Affect Disord"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.2023.79","article-title":"Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): randomised double-blind active-controlled trial","volume":"223","author":"Loo","year":"2023","journal-title":"Br J Psychiatry"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03063-x","article-title":"Extended-release ketamine tablets for treatment-resistant depression: a randomized placebo-controlled phase 2 trial","volume":"30","author":"Glue","year":"2024","journal-title":"Nat Med"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1038\/s44220-023-00140-x","article-title":"Randomized trial of ketamine masked by surgical anesthesia in patients with depression","volume":"1","author":"Lii","year":"2023","journal-title":"Nat Ment Health"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2025.3019","article-title":"Serial ketamine infusions as adjunctive therapy to inpatient care for depression: The KARMA-Dep 2 randomized clinical trial","volume":"82","author":"Jelovac","year":"2025","journal-title":"JAMA Psychiatry"},{"key":"B95","doi-asserted-by":"publisher","first-page":"173","DOI":"10.3390\/ph16020173","article-title":"Safety and tolerability of the acute ketamine treatment in treatment-resistant depression: focus on comorbidities interplay with dissociation and psychomimetic symptoms","volume":"16","author":"W\u0142odarczyk","year":"2023","journal-title":"Pharmaceuticals"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1097\/ms9.0000000000003232","article-title":"Safety considerations and risk mitigation strategies for ketamine use: a comprehensive review","volume":"87","author":"Sayad","year":"2025","journal-title":"Ann Med Surg"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1080\/15563650.2023.2212125","article-title":"The clinical toxicology of ketamine","volume":"61","author":"Schep","year":"2023","journal-title":"Clin Toxicol"},{"key":"B98","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3390\/ph17010016","article-title":"Ketamine, an old\u2013new drug: uses and abuses","volume":"17","author":"Savi\u0107 Vujovi\u0107","year":"2023","journal-title":"Pharmaceuticals"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.3389\/fnana.2022.795231","article-title":"Brain changes associated with long-term ketamine abuse, a systematic review","volume":"16","author":"Strous","year":"2022","journal-title":"Front Neuroanat"},{"key":"B100","doi-asserted-by":"publisher","first-page":"100650","DOI":"10.1016\/j.abrep.2025.100650","article-title":"Associations between substance use treatment and ketamine use: a hypothesis-generating analysis","volume":"23","author":"Qeadan","year":"2025","journal-title":"Addict Behav Rep"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2022.1016439","article-title":"A survey of drug liking and cravings in patients using sublingual or intranasal ketamine for treatment resistant depression: a preliminary evaluation of real world addictive potential","volume":"13","author":"Chubbs","year":"2022","journal-title":"Front Psychiatry"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-021-00846-5","article-title":"Prevention and management of common adverse effects of ketamine and esketamine in patients with mood disorders","volume":"35","author":"Ceban","year":"2021","journal-title":"CNS Drugs"},{"key":"B103","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1016\/j.ajem.2007.12.005","article-title":"Adverse events associated with ketamine for procedural sedation in adults","volume":"26","author":"Strayer","year":"2008","journal-title":"Am J Emergency Med"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.4088\/jcp.13m08852","article-title":"Ketamine safety and tolerability in clinical trials for treatment-resistant depression","volume":"76","author":"Wan","year":"2015","journal-title":"J Clin Psychiatry"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2019.11.028","article-title":"Comprehensive assessment of side effects associated with a single dose of ketamine in treatment-resistant depression","volume":"263","author":"Acevedo-Diaz","year":"2020","journal-title":"J Affect Disord"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.3402\/ehtj.v4i0.7107","article-title":"The epidemiology and patterns of acute and chronic toxicity associated with recreational ketamine use","volume":"4","author":"Kalsi","year":"2011","journal-title":"Emerging Health Threats J"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1016\/j.annemergmed.2025.05.003","article-title":"Emergency department ketamine sedation: frequency and predictors of critical and high-risk adverse events","volume":"86","author":"Green","year":"2025","journal-title":"Ann Emergency Med"},{"key":"B108","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/j.1360-0443.2011.03576.x","article-title":"Ketamine use: a review","volume":"107","author":"Morgan","year":"2012","journal-title":"Addiction"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.4088\/jcp.25f16083","article-title":"Ketamine-associated uropathy during therapeutic and nontherapeutic use","volume":"86","author":"Andrade","year":"2025","journal-title":"J Clin Psychiatry"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1177\/02698811251350267","article-title":"Urological symptoms following ketamine treatment for psychiatric disorders: a systematic review","volume":"39","author":"Kerr-Gaffney","year":"2025","journal-title":"J Psychopharmacol"},{"key":"B111","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1177\/02698811231169647","article-title":"Comment on 'Characteristics of poisonings involving ketamine in the United States, 2019\u20132021'","volume":"37","author":"Pastuszak","year":"2023","journal-title":"J Psychopharmacol"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.20250276","article-title":"Ketamine for depression, but at what cost? a review of ketamine\u2019s neurotoxic effects from preclinical and human studies","volume":"182","author":"Li","year":"2025","journal-title":"Am J Psychiatry"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-021-01120-9","article-title":"Repeated or continuous medically supervised ketamine administration associated with hepatobiliary adverse events: a retrospective case series","volume":"44","author":"Cotter","year":"2021","journal-title":"Drug Saf"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1155\/2024\/8366034","article-title":"A case of hepatotoxicity induced by therapeutic ketamine use for sedation","volume":"2024","author":"Yoo","year":"2024","journal-title":"Case Rep Crit Care"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2011.03.026","article-title":"Drug-induced liver injury following a repeated course of ketamine treatment for chronic pain in CRPS type 1 patients: a report of 3 cases","volume":"152","author":"Noppers","year":"2011","journal-title":"Pain"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1002\/da.22536","article-title":"A review of ketamine abuse and diversion","volume":"33","author":"Sassano\u2010Higgins","year":"2016","journal-title":"Depression Anxiety"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1097\/spc.0b013e328352812c","article-title":"Ketamine for chronic noncancer pain: concerns regarding toxicity","volume":"6","author":"Bell","year":"2012","journal-title":"Curr Opin Supportive Palliative Care"},{"key":"B118","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s11916-025-01408-w","article-title":"Adverse effects associated with high-dose ketamine infusions for refractory pain and psychiatric conditions","volume":"29","author":"Javaheri","year":"2025","journal-title":"Curr Pain Headache Rep"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.0395","article-title":"Comparative safety and tolerability of ketamine and esketamine for major depressive disorder: a systematic review and meta-analysis","volume":"16","author":"Guo","year":"2025","journal-title":"Front Pharmacol"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1111\/add.70073","article-title":"The landscape of ketamine use disorder: patient experiences and perspectives on current treatment options","volume":"120","author":"Harding","year":"2025","journal-title":"Addiction"},{"key":"B121","doi-asserted-by":"publisher","first-page":"55185","DOI":"10.12775\/JEHS.2024.68.55185","article-title":"Recreational ketamine use and its impact on health","volume":"68","author":"Per\u0142owski","year":"2024","journal-title":"J Education Health Sport"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-022-00897-2","article-title":"Non-parenteral ketamine for depression: a practical discussion on addiction potential and recommendations for judicious prescribing","volume":"36","author":"Swainson","year":"2022","journal-title":"CNS Drugs"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1177\/00048674241242315","article-title":"Drug dependence and prescribing ketamine for treatment-resistant depression in Australia and New Zealand","volume":"58","author":"Carroll","year":"2024","journal-title":"Aust New Z J Psychiatry"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2023.4945","article-title":"The rapidly shifting ketamine landscape in the US","volume":"81","author":"Wilkinson","year":"2024","journal-title":"JAMA Psychiatry"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2008.01.024","article-title":"Journey through the K-hole: phenomenological aspects of ketamine use","volume":"95","author":"Muetzelfeldt","year":"2008","journal-title":"Drug Alcohol Depend"},{"key":"B126","article-title":"FDA approves new nasal spray medication for treatment-resistant depression, available only at a certified doctor's office or clinic","year":"2019"},{"key":"B127","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1177\/02698811241273850","article-title":"Ketamine use in a large global sample: characteristics, patterns of use and emergency medical treatment","volume":"39","author":"Barrios","year":"2025","journal-title":"J Psychopharmacol"},{"key":"B128","doi-asserted-by":"publisher","first-page":"02698811251373058","DOI":"10.1177\/02698811251373058","article-title":"Deaths following illicit ketamine use in England, Wales and Northern Ireland 1999\u20132024: an update report to inform the reclassification debate","volume":"40","author":"Pullen","year":"2025","journal-title":"J Psychopharmacol"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1097\/adm.0000000000001340","article-title":"The pharmacological management of ketamine use disorder: a systematic review","volume":"18","author":"Roberts","year":"2024","journal-title":"J Addict Med"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1177\/20420986251347360","article-title":"Abuse liability for esketamine in a cohort of patients undergoing an acute treatment course to manage treatment-resistant depression: a secondary analysis of an observational study in real-world clinical practicee","volume":"16","author":"Gutierrez","year":"2025","journal-title":"Ther Adv Drug Saf"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1192\/j.eurpsy.2022.2148","article-title":"Walking with myself by my side\u201d-non-medical use of Ketamine","volume":"65","author":"Vaz","year":"2022","journal-title":"Eur Psychiatry"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1080\/02791072.2001.10400480","article-title":"The nonmedical use of ketamlne, part two: a review of problent use and dependence","volume":"33","author":"Jansen","year":"2001","journal-title":"J Psychoact Drugs"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.710338","article-title":"An integrative approach to ketamine therapy may enhance multiple dimensions of efficacy: improving therapeutic outcomes with treatment resistant depression","volume":"12","author":"Muscat","year":"2021","journal-title":"Front Psychiatry"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1007\/s43440-021-00232-4","article-title":"Ketamine\u201450 years in use: from anesthesia to rapid antidepressant effects and neurobiological mechanisms","volume":"73","author":"Kohtala","year":"2021","journal-title":"Pharmacol Rep"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1111\/add.15087","article-title":"Global opioid agonist treatment: a review of clinical practices by country","volume":"115","author":"Jin","year":"2020","journal-title":"Addiction"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2018.00742","article-title":"Management of opioid addiction with opioid substitution treatments: beyond methadone and buprenorphine","volume":"9","author":"Noble","year":"2019","journal-title":"Front Psychiatry"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1177\/00048674251396009","article-title":"Ketamine in psychiatry: ethical imperatives in harnessing a controversial yet promising therapy","volume":"60","author":"Can","year":"2026","journal-title":"Aust New Z J Psychiatry"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1017\/s1092852925100333","article-title":"Ketamine in clinical practice: transitioning from anesthetic agent to psychiatric therapeutic","volume":"30","author":"Quintero","year":"2025","journal-title":"CNS Spectrums"}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2026.1866092\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T05:34:44Z","timestamp":1783575284000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2026.1866092\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,9]]},"references-count":138,"alternative-id":["10.3389\/fpsyt.2026.1866092"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2026.1866092","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,9]]},"article-number":"1866092"}}